The collaboration offers customers an end-to-end service incorporating cell line development from Aragen Bioscience with process development and manufacturing from Avid Bioservices. Contract research organization (CRO) Aragen has teamed with contract development and manufacturing organization (CDMO) Avid to provide biopharma customers a package from early cell line development through to cGMP manufacturing. “Many of our prospect customers are requesting expedited timelines to GLP-Tox pilot batch and cGMP drug substance deliveries for their early stage programs,” an Avid spokesperson told Bioprocess…

Emergent Biosolutions says higher demand for CDMO services for COVID-19 related products helped it in the first quarter. Emergent total saw revenues of $192.5 million in Q1, a slight increase over 2019. The firm said total revenues reflect a decline in product sales partially offset by an increase in CDMO and contracts and grants revenues. The firm also maintained its full year guidance – revenues of $1.175 billion to $1.275 billion and net income in the $169 million to $210…